URGN•benzinga•
UroGen Pharma Announces Results From ENVISION And ATLAS Clinical Studies Exploring Investigational Therapy UGN-102 For Intravesical Solution For Treatment For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga